A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers

被引：0
|
作者：
Takashi Eto
Yuji Karasuyama
Verónica González
Ana Del Campo García
机构：
[1] Souseikai Hakata Clinic,Clinical Research Unit
[2] Syneos Health Clinical K.K.,Medical Department
[3] mAbxience Research S.L.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 88卷
关键词：
MB02; Bevacizumab; Biosimilars; Pharmacokinetics; Safety; Japanese;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：713 / 722
页数：9
相关论文
共 50 条
  • [1] A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
    Eto, Takashi
    Karasuyama, Yuji
    Gonzalez, Veronica
    Del Campo Garcia, Ana
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (04) : 713 - 722
  • [2] A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
    Sinn, Angela
    Garcia-Alvarado, Fernanda
    Gonzalez, Veronica
    Huerga, Camino
    Bullo, Felicitas
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (03) : 1063 - 1073
  • [3] A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
    Donghoon Shin
    Yoon Jung Lee
    Jihye Choi
    Dahyoung Lee
    Minjeong Park
    Magdalena Petkova
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 567 - 575
  • [4] A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
    Shin, Donghoon
    Lee, Yoon Jung
    Choi, Jihye
    Lee, Dahyoung
    Park, Minjeong
    Petkova, Magdalena
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 567 - 575
  • [5] Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
    Miguel-Lillo, B.
    Sanchez-Vidaurre, Sara
    Diaz, L. Perez
    Paravisini, A.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (06):
  • [6] A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
    Schwabe, C.
    Cole, A.
    Espigares-Correa, A.
    Beydon, M. E.
    Florez-Igual, A.
    Queiruga-Parada, J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (02):
  • [7] A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
    Hanes, Vladimir
    Chow, Vincent
    Pan, Zhiying
    Markus, Richard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (05) : 899 - 905
  • [8] A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
    Vladimir Hanes
    Vincent Chow
    Zhiying Pan
    Richard Markus
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 899 - 905
  • [9] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Vladimir Hanes
    Vincent Chow
    Nan Zhang
    Richard Markus
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 881 - 888
  • [10] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Hanes, Vladimir
    Chow, Vincent
    Zhang, Nan
    Markus, Richard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 881 - 888
12345